BioMarin Pharmaceutical (HAM:BM8) General and Admin. Expense: €560 Mil (TTM As of Mar. 2026)


HAM:BM8 BioMarin Pharmaceutical Inc HAM:BM8
75 GF Score
Price €51.94
GF Value €77.58
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical General and Admin. Expense?

BioMarin Pharmaceutical HAM:BM8 -0.19% 75 General and Admin. Expense is €560 Mil as of Mar. 2026. GuruFocus rates HAM:BM8 with a GF Score™ of 75/100 and a GF Value™ of €77.58. The stock has 3 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. BioMarin Pharmaceutical's General and Admin. Expense for the three months ended in Mar. 2026 was €115 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €560 Mil.

BioMarin Pharmaceutical General and Admin. Expense Related Terms

BioMarin Pharmaceutical General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical General and Admin. Expense Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 313.56 352.02 370.47 508.35 531.87

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.83 95.54 116.81 232.29 115.39
HAM:BM8
75GF Score
BioMarin Pharmaceutical Inc HAM:BM8
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €560 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €560 Mil mean?
BioMarin Pharmaceutical (HAM:BM8) has a General and Admin. Expense of €560 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's General and Admin. Expense too high?
BioMarin Pharmaceutical's current General and Admin. Expense is €560 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's General and Admin. Expense compare to CYTK and ARWR?
BioMarin Pharmaceutical's General and Admin. Expense of €560 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current General and Admin. Expense is €560 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
BioMarin Pharmaceutical (HAM:BM8) has a current General and Admin. Expense of €560 Mil. The stock's GF Value™ is €77.58, compared to a current price of €51.94 — trading 33% below its estimated fair value. The current General and Admin. Expense is €560 Mil. BioMarin Pharmaceutical's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For BioMarin Pharmaceutical (HAM:BM8), the current General and Admin. Expense is €560 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (HAM:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €51.94 is trading 33% below its estimated GF Value™ of €77.58.

Key valuation signals for HAM:BM8:

  • General and Admin. Expense: €560 Mil
  • GF Value™: €77.58 vs. price of €51.94 (33% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the HAM:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
75GF Score

Get the complete analysis for HAM:BM8

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.94
Price
€77.58
GF Value